Endocan, ET-1, and ETAR Expression Profiles in Unicystic Ameloblastoma, Multicystic Ameloblastoma, and Ameloblastic Carcinoma
File version
Version of Record (VoR)
Author(s)
Mohsenifar, Zhaleh
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
Background: Odontogenic lesions range from simple cysts to benign tumors and carcinomas. Unicystic ameloblastoma is a monocystic lesion and a less aggressive tumor compared to multicystic ameloblastoma. Ameloblastic carcinoma is the malignant variant of the multicystic ameloblastoma and may arise de novo or from malignant transformation of a long-standing multicystic ameloblastoma. Methods:We collected 54 tissue samples obtained from patients from 2000-2017 that were stored in the archives section of the Pathology Department of Taleghani Educational Hospital, Tehran, Iran. The specimens were processed for immunohistochemistry analysis. Immunostaining of the markers was assessed via quantitative methods. Statistical analysis was performed using one-way ANOVA and the chisquare test. Results: One-way ANOVA analysis and the chi-square test did not reveal any statistically significant differences between the expression levels of endocan, ET-1, and ETAR and lesion type. A positive correlation existed between ET-1 and ETAR expression levels in unicystic ameloblastoma and multicystic ameloblastoma (Pearson’s r = 0.506, P<0.002), and between ET-1 and ETAR expression levels in unicystic ameloblastoma and ameloblastic carcinoma (Pearson’s r = 0.376, P<0.024). Conclusion: This study revealed a positive correlation between the histological degree of lesion and endocan, ET-1, and ETAR expression levels. Hence, it might suggest that multicystic ameloblastoma develops from unicystic ameloblastoma. Over time, multicystic ameloblastoma may undergo a malignant transformation to ameloblastic carcinoma. Possibly, a simple cystic neoplasm can progress to a cystic lesion with invasion to the connective tissue wall and a gradual development into a true neoplasm (multicystic ameloblastoma), with potential for malignant transformation (ameloblastic carcinoma). Endocan, ET-1, and ETAR can be used as prognostic biomarkers for different variants of multicystic ameloblastoma and possible new targets for cancer therapy.
Journal Title
Middle East Journal of Cancer
Conference Title
Book Title
Edition
Volume
10
Issue
3
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© The Author(s) 2019. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Item Access Status
Note
Access the data
Related item(s)
Subject
Oncology and carcinogenesis
Science & Technology
Life Sciences & Biomedicine
Oncology
Endothelin-1
Endothelin A receptor
Persistent link to this record
Citation
Irani, S; Mohsenifar, Z, Endocan, ET-1, and ETAR Expression Profiles in Unicystic Ameloblastoma, Multicystic Ameloblastoma, and Ameloblastic Carcinoma, Middle East Journal of Cancer, 2019, 10 (3), pp. 167-174